Takashi Nagao
Vorsitzender bei Medicago, Inc.
Ursprung des Netzwerks ersten Grades von Takashi Nagao
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
MP Healthcare Venture Management, Inc.
 MP Healthcare Venture Management, Inc. Investment ManagersFinance MP Healthcare Venture Management, Inc (MP Healthcare Venture) is a venture capital subsidiary of Mitsubishi Tanabe Pharma Corp founded in 2006. The firm is headquartered in Boston, Massachusetts.
7
| Subsidiary | Investment Managers | 7 |
Medicago, Inc.
 Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada.
7
| Subsidiary | Biotechnology | 7 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Takashi Nagao
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| MITSUBISHI TANABE PHARMA CORPORATION | Pharmaceuticals: Other | Corporate Officer/Principal Public Communications Contact Director/Board Member Corporate Officer/Principal Comptroller/Controller/Auditor Private Equity Investor Director/Board Member | |
| NICOX SA | Pharmaceuticals: Major | Founder | |
| University of Oxford | College/University | Doctorate Degree | |
RCT BioVentures
 RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | Investment Managers | Corporate Officer/Principal | |
| Queen's University | College/University | Graduate Degree | |
| Osaka University | College/University | Undergraduate Degree Doctorate Degree | |
| Massachusetts Institute of Technology | College/University | Masters Business Admin | |
| University of Toronto | College/University | Doctorate Degree | |
| McMaster University | College/University | Corporate Officer/Principal | |
| University of New Brunswick | College/University | Undergraduate Degree | |
| University of Birmingham | College/University | Masters Business Admin | |
| Wilfrid Laurier University | College/University | Undergraduate Degree | |
| Kyoto University | College/University | Undergraduate Degree | |
| Osaka Prefecture University | College/University | Doctorate Degree | |
Canadian Association of Gastroenterology
 Canadian Association of Gastroenterology Miscellaneous Commercial ServicesCommercial Services Canadian Association of Gastroenterology promotes the study of the digestive tract in health and disease. It supports the development and maintenance of formal educational research component within Gastroenterology in Canada. The company was founded in 1962 and is headquartered in Oakville, Canada. | Miscellaneous Commercial Services | President | |
| Harvard Medical School | College/University | Graduate Degree | |
| ANTIBE THERAPEUTICS INC. | Pharmaceuticals: Major | Founder Investor Relations Contact | |
| Meiji Pharmaceutical University | College/University | Undergraduate Degree | |
Antibe Holdings, Inc.
 Antibe Holdings, Inc. Financial ConglomeratesFinance Part of Antibe Therapeutics, Inc., Antibe Holdings, Inc. is a Canadian company that functions as an investment holding company. The company is based in Toronto, Canada. Antibe Holdings was acquired by Antibe Therapeutics, Inc. on June 03, 2021 for $19.02 million. Daniel Legault has been the CEO of the company since 2005. | Financial Conglomerates | Chairman | |
| Cumming School of Medicine | College/University | Corporate Officer/Principal | |
QurAlis Corp.
 QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
| Farncombe Family Digestive Health Research Institute | Director/Board Member | ||
Diamond Edge Ventures, Inc.
 Diamond Edge Ventures, Inc. Investment ManagersFinance Diamond Edge Ventures, Inc (Diamond Edge ventures) is a venture capital subsidiary of Mitsubishi Chemical Holdings Corp founded in 2018. The firm is headquartered in San Francisco, California. | Investment Managers | Director/Board Member | |
Pharmenable Ltd.
 Pharmenable Ltd. Pharmaceuticals: MajorHealth Technology Pharmenable Ltd. operates as a drug discovery company. It designs the next generation of small molecule drugs. The company was founded by Hannah Fiona Sore, Natalia Mateu, Jelena Aleksic, David Spring, and Andreas Bender in June 2016 and is headquartered in Histon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Capsigen, Inc.
 Capsigen, Inc. BiotechnologyHealth Technology Capsigen, Inc. is a company based in Vancouver, WA that is developing the next generation of AAV vectors for gene therapy. The company's end-to-end platform uses customized, diverse libraries and proprietary trade™ technology to identify fully functional vectors that meet disease-specific transduction criteria. Capsigen's fit-for-purpose vectors are designed to deliver the highest level of clinical utility in a rapid and high-throughput manner. The company uses data science and directed evolution to build custom AAV capsids to move patients from hope to cured. John Bial has been the CEO of the company since 2020. | Biotechnology | Director/Board Member | |
SOLA Biosciences LLC
 SOLA Biosciences LLC Pharmaceuticals: MajorHealth Technology SOLA Biosciences LLC is a pre-clinical-stage biopharmaceutical company that develops gene-therapies for patients with neurodegenerative diseases. The company is based in Natick, MA. The company was founded by Akinori Hishiya, Keizo Koya. Keizo Koya has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member |
Statistik
International
| Kanada | 11 |
| Vereinigte Staaten | 10 |
| Japan | 6 |
| Vereinigtes Königreich | 4 |
| Frankreich | 2 |
Sektoral
| Consumer Services | 14 |
| Health Technology | 10 |
| Finance | 5 |
| Commercial Services | 2 |
Operativ
| Director/Board Member | 16 |
| Corporate Officer/Principal | 10 |
| Private Equity Investor | 7 |
| Undergraduate Degree | 7 |
| President | 4 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Takashi Nagao
- Unternehmensverbindungen
